Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$53.00 – $53.00
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $572.4M | $700.9M | $793.8M | $942.9M | $1.02B | $1.15B | $1.18B | $1.16B |
| Cost of revenue | $272.7M | $317.2M | $330.3M | $322.2M | $363.9M | $446.6M | $413.7M | $773.0M |
| Gross profit | $299.8M | $383.7M | $463.5M | $620.7M | $660.8M | $704.1M | $767.1M | $391.6M |
| Gross margin | 52.4% | 54.7% | 58.4% | 65.8% | 64.5% | 61.2% | 65.0% | 33.6% |
| R&D | $7.0M | $11.2M | $12.7M | $14.2M | $13.2M | $19.9M | $11.5M | $11.2M |
| Operating income | $107.5M | $119.5M | $136.9M | $298.5M | $243.7M | $182.9M | $216.9M | $221.7M |
| EBITDA | $140.4M | $168.0M | $182.1M | $357.0M | $323.5M | $262.7M | $320.9M | $314.2M |
| Net income | $75.3M | $77.2M | $85.8M | $209.6M | $134.2M | $62.4M | $113.8M | $132.4M |
| Net margin | 13.2% | 11.0% | 10.8% | 22.2% | 13.1% | 5.4% | 9.6% | 11.4% |
| EPS (diluted) | 1.41 | 1.43 | 1.59 | 3.89 | 2.49 | 1.16 | 2.11 | 2.46 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.2B | $2.64 | $2.60–$2.70 | 1 |
| 2027 | $1.2B | $2.91 | $2.87–$2.98 | 1 |
| 2028 | $1.3B | $3.16 | $3.12–$3.24 | 1 |
| 2029 | $1.3B | $3.36 | $3.32–$3.45 | 1 |
Forward consensus · source: Financial Modeling Prep
DERMAPHARM HLDG SE
No one on the platform currently holds DMPHF.
No tracked institution reports a position in DMPHF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-30 | $0.8800 | 2026-07-01 |
| 2025-06-30 | $0.9000 | 2025-07-01 |
| 2024-07-01 | $0.8800 | 2024-07-02 |
No one on the platform has traded DMPHF yet.
| $2.3B |
| — |
| CURLFCuraleaf Holdings, Inc. | $9.99 | +3.74% | $2.6B | — |
| HMDCFHUTCHMED (China) Limited | $2.90 | +34.26% | $2.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.